Eric Yuen, M.D. is the chief medical officer of Spirovant Sciences, Inc. and a clinical development physician with over 20 years of experience in academia and industry. During his career, Dr. Yuen has developed numerous biologics and small molecule therapeutics for a variety of diseases, including rare genetic diseases and neurology, psychiatry, pain and oncology disorders. Dr. Yuen has led departments responsible for Phase I-IV development and submissions of numerous INDs, CTAs, NDAs and MAAs.
Dr. Yuen was the director of clinical research at Merck & Co., working on CNS and pain indications, and later vice president of clinical development at Johnson & Johnson. While at Johnson & Johnson, Dr. Yuen served as the therapeutic area head for CNS and the head of clinical development at a monoclonal antibodies and vaccines joint venture between Johnson & Johnson and Elan. He later served as chief medical officer of Ultragenyx, a start-up company focused on rare genetic diseases, as vice president of clinical development at BioClin Therapeutics, a start-up focused on the rare genetic disorder achondroplasia (dwarfism) and bladder cancer, and was chief medical officer and co-founder of Talee Bio.
Earlier in his career, Dr. Yuen was an assistant professor of neurology at the University of Washington where he conducted clinical research in rare disorders such as ALS and muscular dystrophies. He received his BA from Stanford University, MD from the University of Chicago, Pritzker School of Medicine, and completed his neurology residency at UCSF and his post-doctoral fellowship at UCSF studying neurotrophic factor signaling.